Search

Author/Creator Mekhail, T.

1. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. (September 2015)

Authors:
Varga, A.; Camidge, D.R.; Sequist, L.V.; Wakelee, H.; Ou, S.H.; Goldman, J.W.; Papadimitrakopoulou, V.; Gadgeel, S.; Mekhail, T.; Oxnard, G.R.; Socinski, M.; Solomon, B.; Yu, H.; Matheny, S.; Despain, D.; Soria, J.C.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S598
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015)

Authors:
Barlesi, F.; Dingemans, A.M.C.; Ou, I.; Ahn, J.S.; Petris, L.D.; Kim, D.W.; Yang, J.C.H.; Hughes, B.; Lena, H.; Moro-Sibilot, D.; Bearz, A.; Viteri, S.; Mekhail, T.; Spira, A.; Zeaiter, A.; Bordogna, W.; Sturm, C.; Golding, S.; Morcos, P.N.; Govindan, R.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S635
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search